Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modulation of postprandial lipemia, inflammation, and vascular function by PCSK9 inhibition in diabetes
2016-003253-15Phase 4Active
- Sponsor
- Franciscus Gasthuis & Vlietland
- Start
- Jan 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of alirocumab in type 2 diabetes mellitus (T2DM), cardiac morbidity, sponsored by Franciscus Gasthuis & Vlietland. Started Jan 2017; status: active.
02
Drugs
alirocumab
03
Conditions
type 2 diabetes mellitus (T2DM)cardiac morbidity
Beyond the preview
Go deeper on 2016-003253-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003253-15.